Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma.
Authors
Jayson, Gordon CVives, Corinne
Paraskeva, Christos
Schofield, Karen P
Coutts, Jacquie
Fleetwood, Alison
Gallagher, John T
Affiliation
Cancer Research Campaign, Department of Medical Oncology, Paterson Institute, Manchester, UK. GordonJayson@Compuserve.comIssue Date
1999-07-19
Metadata
Show full item recordAbstract
Basic fibroblast growth factor (bFGF) is dependent on heparan sulphate for its ability to activate the cell surface signal transducing receptor. We have investigated the FGF dual receptor mechanism in a novel model of the transformation from human colon adenoma to carcinoma in vitro. Reverse transcription-polymerase chain reaction showed that mRNA for FGF receptors 1 and 2 were expressed in both the adenoma and carcinoma cells whereas immunocytochemistry showed that the expression of the FGF R1 was reduced significantly in the carcinoma cells. We have reported previously that the composition and sequence of human colon adenoma and carcinoma heparan sulphate (HS) differ in a defined and specific manner. The functional significance of these changes was assessed by affinity co-electrophoresis, which showed that the affinity of adenoma HS for bFGF was 10-fold greater than that of the carcinoma HS (Kd 220 nM vs. 2493 nM, respectively). In addition, Northern studies of the expression of syndecan 1 and 4 mRNA showed that proteoglycan core protein expression was reduced significantly in the carcinoma cells. These findings were associated with a reduced biological response to bFGF in the carcinoma cells that could be partially reversed by the addition of exogenous heparin, suggesting that both the proteoglycan and signal transducing receptor control the cells' response to bFGF.Citation
Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. 1999, 82 (2):298-304 Int. J. CancerJournal
International Journal of CancerDOI
10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.0.CO;2-9PubMed ID
10389767Type
ArticleLanguage
enISSN
0020-7136ae974a485f413a2113503eed53cd6c53
10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.0.CO;2-9